Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

GW Pharma to launch MS treatment in Germany after regulatory approval

GW Pharma to launch MS treatment in Germany after regulatory approval

GW Pharmaceuticals (LON:GWP) is prepared to launch its Sativex treatment for multiple sclerosis in Germany this July after the country’s health authorities granted regulatory approval for the treatment. Sativex is already available for MS patients in the UK and in Spain.

The medicine is a first-in-class ‘endocannabinoid’ (cannabis-based) system modulator for the treatment of spasticity in MS. It is delivered by a spray that can be delivered into the mouth either onto the inside of the cheek or under the tongue.

Spasticity (also known as muscle stiffness) has a negative impact on patients’ daily lives as it reduces their capacity to carry out everyday activities such as walking and keeping upright, as well as having an impact on their general mobility, bladder function and quality of sleep.

According to GW Pharma, around half of people with MS do not manage to find relief from these symptoms with currently-available treatments.

The firm says that evidence generated from clinical trials shows that Sativex has a positive impact on spasticity in MS, while alleviating associated symptoms.

“Having recently successfully launched Sativex in Spain, we are very pleased to have now received regulatory approval in Germany,” said Justin Gover, GW Pharma’s managing director. “Germany has the largest MS population in Europe and we look forward to offering people with MS in Germany the opportunity to benefit from Sativex as a new first in class treatment to treat their spasticity.”

The approval of the medicine in Germany follows the successful completion in March this March of the European Mutual Recognition Procedure (MRP) with all six countries involved – Germany, Denmark, Sweden, Italy, the Czech Republic and Austria – recommending approval. GW Pharma plans to make a further MRP submission later this year in order to expand the approval of Sativex.

GW Pharma’s share price was up 0.2 per cent at midday today at 120.25 pence.

 

Join our Crypto, Blockchain and Cannabis Telegram group here
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

1539364967_Cannabis-plant.jpg
October 10 2018
Management behind ICC International Cannabis Corp has a clear buy, build and sell strategy
cannabis leaf and green tablets
October 29 2018
The company will now proceed with stage II of the human clinical trial.
cannabis
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use